Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial

Immunogenicity and safety of concurrent or sequential administration of live, attenuated SA 14-14-2 Japanese encephalitis vaccine (CD-JEV) and measles-mumps-rubella vaccine in infants 9–12 months of age in the Philippines: A non-inferiority Phase 4 randomized clinical trial

Introduction: Japanese encephalitis (JE) virus is the leading cause of viral encephalitis across temperate and tropical zones of Asia. The live attenuated SA 14-14-2 JE vaccine (CD-JEV) is one of three vaccines prequalified by the World Health Organization (WHO) to prevent JE. When incorporating a n...

Full description

Bibliographic Details
Main Authors: Maria Rosario Capeding, Edison Alberto, Jodi Feser, Jessica Mooney, Yuxiao Tang, Susette A. Audet, Judy A. Beeler, Damon W. Ellison, Lei Zhang, G. William Letson, Kathleen M. Neuzil, Anthony A. Marfin
Format: Article
Language:English
Published: Elsevier 2020-12-01
Series:Vaccine: X
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136220300218

Internet

http://www.sciencedirect.com/science/article/pii/S2590136220300218

Similar Items